View Alert


Originator: DHSC & NHS England and Improvement: Supply disruption alert

 
Issue date: 22-May-2020 13:24:13

Action by recipients:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities
  • Acute Trusts
  • Community Trusts

Information to recipients:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • DHSC Supply Disruption - Medicines

Action category: Immediate Action

Title: Supply Disruption Alert: Update - Neuromuscular blocking agents: atracurium, cisatracurium and rocuronium

Broadcast content:

This supply disruption alert update supersedes the update (SDA/2020/004(R)) issued on 16th April 2020.

The supply position on rocuronium has now substantially improved. Therefore, Trusts can now use rocuronium as a first-choice neuromuscular blocking agent (NMBA) in all scenarios as they choose, unless there is a contraindication.

This alert contains further information and advice on the management of affected patients.

Given the links to covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type. 

Please note that no response is required via the CAS website to this alert.



Additional information: This alert is not relevant to Primary Care.

Alert reference: SDA/2020/004(R)(U)

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency